Five Prime Therapeutics, Inc. (Nasdaq: FPRX) announced the advancement of FPA008 into the Phase 2 dose expansion portion of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE